Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis

Hepatology

Volumn 58, Issue 6, 2013, Pages 1877-1880

  Reeder, Scott B ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BIOLOGICAL MARKER; COLESEVELAM; FAT; PLACEBO; PROTON; PROTON DENSITY FAT FRACTION; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; FATTY LIVER; GLYCEMIC CONTROL; GOLD STANDARD; HEPATITIS; HUMAN; IONIZING RADIATION; IRON OVERLOAD; LIVER BIOPSY; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN CONCENTRATION; PRIORITY JOURNAL; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE WATER; TRIACYLGLYCEROL BLOOD LEVEL; WATER CONTENT; FEMALE; MALE; PATHOLOGY; PROCEDURES;

BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84888290605     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26543     Document Type: Article

References (21)

1. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le T-A, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930-1940.
2. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.
3. Fananapazir G, Zhong X, Burke L, Dale B, Kiefer B, Boll B, et al. Initial in vivo validation of a hybrid magnitude/complex MRI-based method for liver fat quantification. In: International Society of Magnetic Resonance in Medicine 21st Meeting, Salt Lake City, Utah; 2013. p 283.
4. Meisamy S, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, Yu H, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011;258:767-775.
5. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009;251:67-76.
6. Yokoo T, Shiehmorteza M, Hamilton G, Wolfson T, Schroeder ME, Middleton MS, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 2011;258:749-759.
7. Bydder M, Yokoo T, Hamilton G, Middleton MS, Chavez AD, Schwimmer JB, et al. Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging 2008;26:347-359.
8. Hernando D, Hines CD, Yu H, Reeder SB. Addressing phase errors in fat-water imaging using a mixed magnitude/complex fitting method. Magn Reson Med 2012;67:638-644.
9. Hines CD, Yu H, Shimakawa A, McKenzie CA, Brittain JH, Reeder SB. T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. J Magn Reson Imaging 2009;30:1215-1222.
10. Liu CY, McKenzie CA, Yu H, Brittain JH, Reeder SB. Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med 2007;58:354-364.
11. Yu H, Shimakawa A, Hines CD, McKenzie CA, Hamilton G, Sirlin CB, et al. Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med 2011;66:199-206.
12. Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med 2008;60:1122-1134.
13. Rehm J, Wolfgram P, Connor E, Zha W, Allen D, Hernando D, et al. Proton density fat fraction is a highly accurate biomarker of hepatic steatosis in adolescent girls and young women. In: International Society of Magnetic Resonance in Medicine 21st Meeting; Salt Lake City, Utah; 2013. p 402.
14. Hines CD, Agni R, Roen C, Rowland I, Hernando D, Bultman E, et al. Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. J Magn Reson Imaging 2012;35:844-851.
15. Hines CD, Frydrychowicz A, Hamilton G, Tudorascu DL, Vigen KK, Yu H, et al. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging 2011;33:873-881.
16. Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging 2012;36:1011-1014.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
18. Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267:767-775.
19. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013;267:422-431.
20. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011;54:773-794.
21. Cohen JD, Costa HS, Russo RJ. Determining the risks of magnetic resonance imaging at 1.5 Tesla for patients with pacemakers and implantable cardioverter defibrillators. Am J Cardiol 2012;110:1631-1636.